OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Investigator: Brian Della Valle

1 Projects | 1 Researchers | $598,253 Invested

2024

GLX Analytix ApS

Brian Della Valle, Phd

The GLX Signature test for diagnosis and monitoring of Alzheimer’s Disease at the point-of-care.

  • Funding Amount: $598,253
  • Organization Type: Biotechnology/For Profit
  • Program: Biomarkers
  • Target: Vascular
  • Status: Active